Sotagliflozin: A Potential Test Of Patient-Physician Decision-Making
Sanofi's proposed type 1 diabetes treatment may be beneficial for some patients who want more glycemic control and are willing to perform the necessary monitoring, but how would the US FDA define that population in the label?
